Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants.

@article{Poirot2015RisksOH,
  title={Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants.},
  author={Eugenie Poirot and Eric Vittinghoff and D. R. S. Ishengoma and Michael Alifrangis and Ilona A. M. Carneiro and Ramadhan Hashim and Vito Baraka and Jackline F Mosha and Samwel Gesase and Daniel DC Chandramohan and Roland D. Gosling},
  journal={PloS one},
  year={2015},
  volume={10 11},
  pages={e0142414}
}
BACKGROUND Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-phosphate dehydrogenase deficient (G6PDd) children. Few studies have explored the effects of G6PD status on hemolysis in children treated with Intermittent Preventive Treatment in infants (IPTi) antimalarial regimens. We sought to examine the joint effects of G6PD… CONTINUE READING